title: Reply to D. Serraino et al.
authors: Dana-Farber Cancer Institute, Boston, MA.
authors: Ann H
authors: AH
authors: Partridge
authors: Shari
authors: S
authors: Gelber
authors: Richard
authors: R
authors: Gelber
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases